PI3K/AKT/mTOR pathway in angiogenesis

被引:1009
|
作者
Karar, Jayashree [1 ,2 ]
Maity, Amit [1 ,2 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
来源
关键词
angiogenesis; PI3K/AKT/mTOR; VEGF; nitric oxide; angiopoietins; ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; FACTOR RECEPTOR INHIBITION; HUMAN GLIOBLASTOMA CELLS; NITRIC-OXIDE PRODUCTION; INDUCIBLE FACTOR-I; H-RAS; VEGF EXPRESSION; CANCER-CELLS; REGULATES ANGIOGENESIS;
D O I
10.3389/fnmol.2011.00051
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The phosphatidylinositol 3-kinase (P13K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in the majority of human cancers. This pathway is known to play a key role in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival, but in the current review we focus on its role in angiogenesis. PI3K activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or by increased expression of growth factor receptors such as epidermal growth factor receptor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to HIF-1 alpha stabilization and is a major stimulus for increased vascular endothelial growth factor (VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) dependent and independent mechanisms. The PI3K/AKT pathway also modulates the expression of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on tumor vasculature can be difficult to predict. The vasculature of tumors is aberrant, leading to sluggish bloodflow and elevated interstitial blood pressure, which can be perpetuated by the high levels of VEGF Hence, decreasing VEGF expression can paradoxically lead to vascular normalization and improved bloodflow in some tumors. In addition to its importance in cancer, the PI3K pathway also plays an essential role in the formation of normal blood vessels during development. Embryos with kinase-dead p110a catalytic subunit of PI3K develop vascular defects. Stimulation of endothelial cells byVEGF leads to activation of the PI3K pathway within these cells, which is important for cell migration. Sustained endothelial activation of AKT1 has been shown to induce the formation of structurally abnormal blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway plays an important role in regulating angiogenesis both in normal tissues and in cancers.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway
    Yu, Jie-ru
    Liu, Yu-yue
    Gao, Yang-yang
    Qian, Li-hui
    Qiu, Jia-lin
    Wang, Pei-pei
    Zhang, Guang-ji
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 324
  • [32] Leonurine inhibits breast cancer cell growth and angiogenesis via PI3K/AKT/mTOR pathway
    Tian, Junjun
    Peng, Lizhong
    Wang, Dongjie
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2023, 22 (03) : 509 - 515
  • [33] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [34] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [35] Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma
    Shao, Weilin
    Feng, Yan
    Huang, Jin
    Li, Tingyu
    Gao, Shengguai
    Yang, Yihao
    Li, Dongqi
    Yang, Zuozhang
    Yao, Zhihong
    OPEN LIFE SCIENCES, 2024, 19 (01):
  • [36] The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
    Slomovitz, Brian M.
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5856 - 5864
  • [37] Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
    Mortazavi, Motahareh
    Moosavi, Fatemeh
    Martini, Miriam
    Giovannetti, Elisa
    Firuzi, Omidreza
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 176
  • [38] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Cidado, Justin
    Park, Ben Ho
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2012, 17 (3-4) : 205 - 216
  • [39] The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
    Monsalves, Eric
    Juraschka, Kyle
    Tateno, Toru
    Agnihotri, Sameer
    Asa, Sylvia L.
    Ezzat, Shereen
    Zadeh, Gelareh
    ENDOCRINE-RELATED CANCER, 2014, 21 (04) : R331 - R344
  • [40] Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
    R. Reilly
    M. S. Mroz
    E. Dempsey
    K. Wynne
    S. J. Keely
    E. F. McKone
    C. Hiebel
    C. Behl
    J. A. Coppinger
    Scientific Reports, 7